Boehringer Ingelheim Clinical Trial Pipeline — 215 Active Studies

Phase 1: 117, Phase 2: 34, Phase 3: 38, Other: 26

Boehringer Ingelheim is a privately-held pharmaceutical company with major franchises in respiratory disease, metabolic conditions, and oncology. In respiratory, Ofev (nintedanib) for idiopathic pulmonary fibrosis and other fibrosing ILDs continues expanding into new fibrosing lung conditions, while Spiriva and Spiolto anchor the COPD franchise. In metabolic disease, Jardiance (empagliflozin) — co-developed with Eli Lilly — has expanded from type 2 diabetes into heart failure with reduced and preserved ejection fraction, and is advancing into CKD. Their oncology pipeline focuses on novel mechanisms in solid tumors, including KRAS SOS1 inhibitors, KRASG12C inhibitors, and immune cell engagers targeting tumor microenvironment.

• Respiratory (IPF, ILD, COPD)
• Metabolic / cardiovascular (SGLT2, HFpEF)
• Oncology (KRAS, SOS1, tumor microenvironment)
• Immunology / inflammation
• CNS

• Jardiance (empagliflozin) — SGLT2, T2D/HF/CKD
• Ofev (nintedanib) — FGFR, PDGFR, VEGFR
• Gilotrif (afatinib) — EGFR/HER2 inhibitor, NSCLC
• BI 1701963 — SOS1 inhibitor, KRAS-mutant tumors
• BI 905677 — KRASG12C inhibitor
• Spesolimab — IL-36R, generalized pustular psoriasis

Boehringer Ingelheim's SOS1 inhibitor (BI 1701963) in combination with KRAS G12C inhibitors is a major competitive program for anyone active in KRAS-altered NSCLC or CRC. Their Jardiance expansions into HFpEF and CKD are closely watched by companies developing competing SGLT2 or HF therapeutics.

DataLookout monitors ClinicalTrials.gov daily and surfaces changes to Boehringer Ingelheim's registered studies: new trial registrations, status transitions (for example "Not yet recruiting" to "Recruiting"), site additions, and protocol amendments. This is the intelligence layer that bridges the gap between quarterly investor calls and day-to-day pipeline developments.

• Sponsor normalization: Boehringer Ingelheim may register trials under multiple legal entity names. DataLookout normalizes all related entities to a single canonical sponsor for complete pipeline coverage.
• Daily updates: ClinicalTrials.gov is queried each morning. New registrations and updates appear in that day's digest.
• Field-level change detection: Status changes, enrollment updates, and site additions are detected and surfaced, not just new registrations.
• Phase filtering: Focus on Phase 3 pivotal trials, Phase 2 proof-of-concept studies, or all phases for comprehensive coverage.
• Indication filtering: Combine sponsor monitoring with indication keywords to focus on the therapeutic areas relevant to your business.